Aliases & Classifications for Lobular Neoplasia

MalaCards integrated aliases for Lobular Neoplasia:

Name: Lobular Neoplasia 12 15 70
Lobular Carcinoma in Situ 12 32
Lobular Carcinoma in Situ of Breast 70
Non-Infiltrating Lobular Carcinoma 70
Lobular Intraepithelial Neoplasia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3010
NCIt 50 C27939
ICD10 32 D05.0
UMLS 70 C0279563 C0334381 C0861352

Summaries for Lobular Neoplasia

Disease Ontology : 12 A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast.

MalaCards based summary : Lobular Neoplasia, also known as lobular carcinoma in situ, is related to comedo carcinoma and papillary carcinoma. An important gene associated with Lobular Neoplasia is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Tamoxifen and Afimoxifene have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and lung, and related phenotypes are Decreased cell migration and Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading

Wikipedia : 73 Lobular neoplasia can refer... more...

Related Diseases for Lobular Neoplasia

Diseases related to Lobular Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 30.6 PGR ESR1 ERBB2
2 papillary carcinoma 30.1 PGR MUC1 ESR1 ERBB2 CDH1
3 gynecomastia 30.0 PGR ESR2 ESR1 ERBB2
4 small cell carcinoma 30.0 MUC1 ERBB2 BRCA2
5 breast fibroadenoma 30.0 PGR ESR1 ERBB2 CT45A10 BRCA1
6 tubular adenocarcinoma 29.9 PGR MUC1 ESR1 ERBB2 CTNNB1 CDH1
7 hypertrophy of breast 29.9 PGR ESR1 ERBB2 BRCA2 BRCA1
8 bilateral breast cancer 29.7 PGR ESR1 ERBB2 CDH1 BRCA2 BRCA1
9 rhabdomyosarcoma 29.7 ESR1 ERBB2 CTNNB1 BRCA2 BRCA1
10 gastric cancer, hereditary diffuse 29.6 CTNND1 CTNNB1 CTNNA1 CDH1 BRCA2 BRCA1
11 intraductal papilloma 29.5 PGR KRT5 ESR1 ERBB2
12 esophageal cancer 29.5 MUC1 MIR375 ERBB2 CTNNB1 CDH1 BRCA2
13 ductal carcinoma in situ 29.2 PIP PGR MUC1 KRT5 ESR2 ESR1
14 in situ carcinoma 28.7 PIP PGR MUC1 KRT5 ESR1 ERBB2
15 breast disease 28.6 PRLR PGR KRT5 ESR2 ESR1 ERBB2
16 breast carcinoma in situ 28.5 PGR KRT5 ESR1 ERBB2 CTNNB1 CT45A10
17 breast ductal carcinoma 27.8 PIP PGR MUC1 KRT5 ESR2 ESR1
18 breast cancer 27.8 PRLR PIP PGR MUC1 KRT5 HSP90AA1
19 nonmucinous bronchioloalveolar adenocarcinoma 10.4 ESR2 ESR1
20 gallbladder signet ring cell adenocarcinoma 10.4 MUC1 CDH1
21 vulvar intraepithelial neoplasia 10.4 CTNNB1 CDH1
22 bile duct cystadenoma 10.4 ESR2 ESR1
23 postmenopausal atrophic vaginitis 10.4 ESR2 ESR1
24 goblet cell carcinoid 10.4 CTNNB1 CDH1
25 bartholin's gland adenoma 10.4 PGR ESR1
26 bartholin's gland adenoid cystic carcinoma 10.4 PGR ESR1
27 uterine corpus adenosarcoma 10.4 PGR ESR1
28 bartholin's gland benign neoplasm 10.4 PGR ESR1
29 vestibular gland benign neoplasm 10.4 PGR ESR1
30 granulomatous endometritis 10.4 PGR ESR1
31 lung leiomyoma 10.4 PGR ESR1
32 liver adenomatosis 10.4 PGR CTNNB1
33 adult type testicular granulosa cell tumor 10.4 PGR ESR1
34 cervical clear cell adenocarcinoma 10.4 PGR ESR1
35 ovarian seromucinous carcinoma 10.3 PGR ESR1
36 endometrial mucinous adenocarcinoma 10.3 PGR MUC1
37 liver leiomyoma 10.3 PGR ESR1
38 pseudomyxoma peritonei 10.3 MUC1 CTNNB1 CDH1
39 euryblepharon 10.3 CTNND1 CDH1
40 intravascular fasciitis 10.3 ESR1 CTNNB1
41 submandibular gland cancer 10.3 HSP90AA1 ERBB2
42 intravenous leiomyomatosis 10.3 PGR ESR1
43 apocrine adenosis of breast 10.3 PGR ERBB2
44 intracranial meningioma 10.3 PGR ESR1
45 chronic tympanitis 10.3 PGR MUC1 ESR1
46 gender identity disorder 10.3 PGR ESR2 ESR1
47 progesterone resistance 10.3 PGR ESR2 ESR1
48 vaginal cancer 10.3 PGR ESR2 ESR1
49 estrogen excess 10.3 PGR ESR2 ESR1
50 vulvar leiomyoma 10.3 PGR ESR1

Graphical network of the top 20 diseases related to Lobular Neoplasia:



Diseases related to Lobular Neoplasia

Symptoms & Phenotypes for Lobular Neoplasia

GenomeRNAi Phenotypes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 8.65 CASK
2 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.32 CTNNB1

MGI Mouse Phenotypes related to Lobular Neoplasia:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
2 endocrine/exocrine gland MP:0005379 10.25 BRCA1 BRCA2 CDH1 CTNNA1 CTNNB1 CTNND1
3 digestive/alimentary MP:0005381 10.22 BRCA1 BRCA2 CASK CDH1 CTNNB1 CTNND1
4 growth/size/body region MP:0005378 10.22 BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
5 integument MP:0010771 10.18 BRCA1 BRCA2 CASK CDH1 CTNNA1 CTNNB1
6 embryo MP:0005380 10.16 BRCA1 BRCA2 CD2BP2 CDH1 CTNNA1 CTNNB1
7 mortality/aging MP:0010768 10.1 BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
8 limbs/digits/tail MP:0005371 10.06 BRCA1 BRCA2 CASK CTNNA1 CTNNB1 ERBB2
9 neoplasm MP:0002006 9.9 BRCA1 BRCA2 CDH1 CTNNA1 CTNNB1 CTNND1
10 reproductive system MP:0005389 9.73 BRCA1 BRCA2 CASK CDH1 CTNNB1 ERBB2
11 skeleton MP:0005390 9.36 BRCA1 BRCA2 CASK CTNNA1 CTNNB1 ERBB2

Drugs & Therapeutics for Lobular Neoplasia

Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
2
Afimoxifene Investigational Phase 2, Phase 3 68392-35-8
3 Hydroxytamoxifen Phase 2, Phase 3
4 Hormones Phase 2, Phase 3
5 Estrogen Antagonists Phase 2, Phase 3
6 Estrogen Receptor Antagonists Phase 2, Phase 3
7 Hormone Antagonists Phase 2, Phase 3
8 Antineoplastic Agents, Hormonal Phase 2, Phase 3
9 Estrogens Phase 2, Phase 3
10 Estrogen Receptor Modulators Phase 2, Phase 3
11
Epirubicin Approved Phase 2 56420-45-2 41867
12
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
13
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
14
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
15
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3
17
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
18 Tubulin Modulators Phase 2
19 Antirheumatic Agents Phase 2
20 Antineoplastic Agents, Immunological Phase 2
21 Immunosuppressive Agents Phase 2
22 Angiogenesis Inhibitors Phase 2
23 Antimitotic Agents Phase 2
24 Antibiotics, Antitubercular Phase 2
25 Alkylating Agents Phase 2
26 Anti-Bacterial Agents Phase 2
27 Immunologic Factors Phase 2
28 Antimetabolites Phase 2
29
Iodine Approved, Investigational 7553-56-2 807
30
Zinc Approved, Investigational 7440-66-6 32051

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ Not yet recruiting NCT04570956 Phase 2, Phase 3 Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo
2 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
3 GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope Unknown status NCT00536718
4 Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study Completed NCT01841749
5 Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ Completed NCT00620087
6 The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy Completed NCT00146536
7 Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice) Recruiting NCT04496739
8 Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ Active, not recruiting NCT00581750

Search NIH Clinical Center for Lobular Neoplasia

Genetic Tests for Lobular Neoplasia

Anatomical Context for Lobular Neoplasia

MalaCards organs/tissues related to Lobular Neoplasia:

40
Breast, Ovary, Lung, Lymph Node, Colon, Skin, Prostate

Publications for Lobular Neoplasia

Articles related to Lobular Neoplasia:

(show top 50) (show all 1160)
# Title Authors PMID Year
1
Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. 61
33778488 2021
2
Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. 61
33685728 2021
3
Identification of a localization wire tip in an occult breast lesion using a handheld magnetometer. 61
33754504 2021
4
The lobular neoplasia enigma: management and prognosis in a long follow-up case series. 61
33736652 2021
5
Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. 61
32861439 2021
6
High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management. 61
33439046 2021
7
Contrast-Enhanced Digital Mammography Screening for Intermediate-Risk Women With a History of Lobular Neoplasia. 61
33787291 2021
8
Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended? 61
32816199 2021
9
Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community. 61
32822256 2021
10
Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution. 61
33068196 2021
11
Impact of lobular carcinoma in situ on local recurrence in breast cancer treated with breast conservation therapy: a systematic review and meta-analysis. 61
33634956 2021
12
Longitudinal study of breast cancer risk markers. 61
33099843 2021
13
Lobular carcinoma in situ: diagnostic criteria and molecular correlates. 61
33024303 2021
14
Ductal and lobular carcinoma in situ arising within an enlarging biopsy proven fibroadenoma. 61
33468635 2021
15
[Overall survival and survival without local recurrence in case of radiotherapy of the tumor bed of ductal carcinomas in situ of the breast: Review of the literature]. 61
33401020 2021
16
Classical Lobular Carcinoma In Situ Arising From an Intraductal Papilloma of the Breast: A Case Report. 61
33403884 2021
17
Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions. 61
33010022 2021
18
[A Case of Lobular Carcinoma In Situ Occurring in a Fibroadenoma of the Breast]. 61
33468741 2021
19
Lobular intraepithelial neoplasia: Outcomes and optimal management. 61
33270304 2020
20
Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided biopsy: can we estimate upgrade on surgical pathology? 61
32888139 2020
21
B3 lesion upgrade rates in a tertiary Australian breast centre: a 8-year experience (2012-2019). 61
32969161 2020
22
Descriptive study comparing outcomes of classic and nonclassic lobular carcinoma in situ (florid and pleomorphic) initially diagnosed on core needle biopsy. 61
33047861 2020
23
Clinical outcomes of patients with ductal carcinoma in situ in Hong Kong: 10-year territory-wide cancer registry study. 61
33277445 2020
24
E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. 61
32572153 2020
25
Preneoplasia of the Breast and Molecular Landscape. 61
32972772 2020
26
Dynamic Changes of Convolutional Neural Network-based Mammographic Breast Cancer Risk Score Among Women Undergoing Chemoprevention Treatment. 61
33277192 2020
27
Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity? 61
32563761 2020
28
Improving contrast and spatial resolution in crystal analyzer-based x-ray dark-field imaging: Theoretical considerations and experimental demonstration. 61
32770681 2020
29
Baseline Screening MRI Uptake and Findings in Women with ≥ 20% Lifetime Risk of Breast Cancer. 61
32683633 2020
30
Benign breast papillomas without atypia diagnosed with core needle biopsy: Outcome of surgical excision and imaging follow-up. 61
32905954 2020
31
Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. 61
32861602 2020
32
Pleomorphic lobular carcinoma in situ composed of signet ring cells mimicking cribriform ductal carcinoma in situ. 61
32588511 2020
33
Role of vacuum assisted excision in minimising overtreatment of ductal atypias. 61
32919262 2020
34
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. 61
32432359 2020
35
Clinicopathologic update of calcium oxalate in breast: A 15-year retrospective review. 61
32564487 2020
36
Lesions of uncertain malignant potential of the breast (B3) on vacuum-assisted biopsy for microcalcifications: Predictors of malignancy. 61
32795765 2020
37
Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. 61
32081572 2020
38
Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity. 61
32317606 2020
39
Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. 61
32673685 2020
40
Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease. 61
32741042 2020
41
Pathologic Evaluation of Breast Tissue From Transmasculine Individuals Undergoing Gender-Affirming Chest Masculinization. 61
31816268 2020
42
Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. 61
31932682 2020
43
[Histological lesions of risk of breast carcinoma. Survival guide for the general pathologist]. 61
32650967 2020
44
Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? 61
31898097 2020
45
Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment. 61
32700071 2020
46
ASO Author Reflections: Conceptualizing Risk in Women with Lobular Carcinoma In Situ. 61
32246310 2020
47
Inter-observer reproducibility of classical lobular neoplasia (B3 lesions) in preoperative breast biopsies: a study of the Swiss Working Group of breast and gynecopathologists. 61
32232656 2020
48
Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. 61
31907376 2020
49
Three-year Trends in Diagnosis of B3 Breast Lesions and Their Upgrade Rates to Malignant Lesions. 61
32171702 2020
50
Non-invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas. 61
32500575 2020

Variations for Lobular Neoplasia

Cosmic variations for Lobular Neoplasia:

9 (show top 50) (show all 3541)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264551 ZRSR2 breast,NS,carcinoma,lobular carcinoma c.772-1G>C p.? 23:15818586-15818586 6
2 COSM87279654 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4556C>G p.S1519* 16:72798126-72798126 6
3 COSM149285883 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4556C>G p.S1519* 16:72798126-72798126 6
4 COSM149315898 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.7262C>G p.S2421* 16:72795420-72795420 6
5 COSM102029000 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.1814C>G p.S605* 16:72798126-72798126 6
6 COSM102040958 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4520C>G p.S1507* 16:72795420-72795420 6
7 COSM102023834 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.6478C>T p.Q2160* 16:72793462-72793462 6
8 COSM149270832 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.9220C>T p.Q3074* 16:72793462-72793462 6
9 COSM87290679 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.7262C>G p.S2421* 16:72795420-72795420 6
10 COSM87274898 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.9220C>T p.Q3074* 16:72793462-72793462 6
11 COSM136835751 YES1 breast,NS,carcinoma,lobular carcinoma c.1105G>C p.D369H 18:739782-739782 6
12 COSM152021957 YES1 breast,NS,carcinoma,lobular carcinoma c.1090G>C p.D364H 18:739782-739782 6
13 COSM89893843 YES1 breast,NS,carcinoma,lobular carcinoma c.1090G>C p.D364H 18:739782-739782 6
14 COSM133268543 YAP1 breast,NS,carcinoma,lobular carcinoma c.1078C>T p.Q360* 11:102223703-102223703 6
15 COSM145023934 YAP1 breast,NS,carcinoma,lobular carcinoma c.964C>T p.Q322* 11:102223703-102223703 6
16 COSM128447630 YAP1 breast,NS,carcinoma,lobular carcinoma c.952C>T p.Q318* 11:102223703-102223703 6
17 COSM127994003 YAP1 breast,NS,carcinoma,lobular carcinoma c.1066C>T p.Q356* 11:102223703-102223703 6
18 COSM126968980 YAP1 breast,NS,carcinoma,lobular carcinoma c.580C>T p.Q194* 11:102223703-102223703 6
19 COSM85232645 YAP1 breast,NS,carcinoma,lobular carcinoma c.1114C>T p.Q372* 11:102223703-102223703 6
20 COSM143037036 YAP1 breast,NS,carcinoma,lobular carcinoma c.1126C>T p.Q376* 11:102223703-102223703 6
21 COSM90943480 YAP1 breast,NS,carcinoma,lobular carcinoma c.1012C>T p.Q338* 11:102223703-102223703 6
22 COSM101979646 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 6
23 COSM104239359 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 6
24 COSM104241154 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 6
25 COSM104886058 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 6
26 COSM101981526 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 6
27 COSM104888500 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 6
28 COSM108081568 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 6
29 COSM92178574 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 6
30 COSM94288275 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 6
31 COSM90876009 WNK1 breast,NS,carcinoma,lobular carcinoma c.6569C>G p.S2190C 12:900596-900596 6
32 COSM130224650 WNK1 breast,NS,carcinoma,lobular carcinoma c.7349C>G p.S2450C 12:900596-900596 6
33 COSM128151609 WNK1 breast,NS,carcinoma,lobular carcinoma c.7808C>G p.S2603C 12:900596-900596 6
34 COSM132334333 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 6
35 COSM132334343 WNK1 breast,NS,carcinoma,lobular carcinoma c.5825C>G p.S1942C 12:900596-900596 6
36 COSM90876002 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 6
37 COSM130224638 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 6
38 COSM92011980 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 6
39 COSM128151601 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 6
40 COSM92011987 WNK1 breast,NS,carcinoma,lobular carcinoma c.7325C>G p.S2442C 12:900596-900596 6
41 COSM88292485 VHL breast,NS,carcinoma,lobular carcinoma c.241C>T p.P81S 3:10142088-10142088 6
42 COSM90665450 VHL breast,NS,carcinoma,lobular carcinoma c.439C>G p.L147V 3:10149885-10149885 6
43 COSM90653017 VHL breast,NS,carcinoma,lobular carcinoma c.241C>T p.P81S 3:10142088-10142088 6
44 COSM88303015 VHL breast,NS,carcinoma,lobular carcinoma c.562C>G p.L188V 3:10149885-10149885 6
45 COSM133858401 USP28 breast,NS,carcinoma,lobular carcinoma c.1675G>A p.D559N 11:113809177-113809177 6
46 COSM83992324 USP28 breast,NS,carcinoma,lobular carcinoma c.2050G>A p.D684N 11:113809177-113809177 6
47 COSM132241970 USP28 breast,NS,carcinoma,lobular carcinoma c.1174G>A p.D392N 11:113809177-113809177 6
48 COSM140659623 TTN breast,NS,carcinoma,lobular carcinoma c.97193-1G>C p.? 2:178542564-178542564 6
49 COSM96773374 TTN breast,NS,carcinoma,lobular carcinoma c.10945G>A p.E3649K 2:178741574-178741574 6
50 COSM139462905 TTN breast,NS,carcinoma,lobular carcinoma c.40301G>A p.R13434K 2:178621600-178621600 6

Expression for Lobular Neoplasia

Search GEO for disease gene expression data for Lobular Neoplasia.

Pathways for Lobular Neoplasia

Pathways related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 PIP MUC1 ESR2 ESR1 ERBB2 CTNND1
2
Show member pathways
13.25 PIP ERBB2 CTNND1 CTNNB1 CTNNA1 CDH1
3
Show member pathways
12.73 HSP90AA1 ERBB2 CTNNB1 CTNNA1 CDH1 BRCA2
4
Show member pathways
12.66 ESR1 ERBB2 CTNNB1 CTNNA1 CDH1
5
Show member pathways
12.65 CTNND1 CTNNB1 CTNNA1 CDH1 CASK
6
Show member pathways
12.6 ESR2 ESR1 ERBB2 CDH1 BRCA2 BRCA1
7 12.48 HSP90AA1 ESR2 ESR1 ERBB2 CTNNB1 CTNNA1
8
Show member pathways
12.41 PRLR ESR2 ESR1 ERBB2
9
Show member pathways
12.33 HSP90AA1 ESR1 CTNNB1 BRCA1
10
Show member pathways
12.23 MUC1 HSP90AA1 ERBB2 CTNNB1 CDH1
11
Show member pathways
12.16 HSP90AA1 CTNND1 CTNNB1 CTNNA1
12 12.04 PGR HSP90AA1 ESR2 ESR1
13 12.04 ESR1 CTNNB1 CDH1 BRCA2 BRCA1
14 12.03 CTNND1 CTNNB1 CTNNA1 CDH1
15
Show member pathways
11.94 PGR ESR2 ESR1 ERBB2 CTNNB1 CTNNA1
16
Show member pathways
11.9 PRLR PGR ESR1 ERBB2
17 11.89 MUC1 CTNND1 CTNNB1 CTNNA1 CDH1
18
Show member pathways
11.79 CTNND1 CTNNB1 CDH1
19
Show member pathways
11.78 PGR ESR2 ESR1
20 11.7 CTNNB1 CTNNA1 CDH1
21 11.38 CTNND1 CTNNB1 CTNNA1
22 11.38 CTNND1 CTNNB1 CTNNA1 CDH1
23 11.29 CTNND1 CTNNB1 CTNNA1
24 11.27 PRLR PGR ESR2
25 11.27 CTNND1 CTNNB1 CTNNA1 CDH1
26 11.26 CTNND1 CTNNB1 CTNNA1
27 11.22 CTNND1 CTNNB1 CTNNA1 CDH1
28 11.2 ERBB2 CTNND1 CTNNB1 CTNNA1 CDH1
29 11.12 CTNNB1 CTNNA1 CDH1
30 11.08 CTNND1 CTNNB1 CTNNA1 CDH1
31 10.99 CTNND1 CTNNA1 CDH1
32 10.78 CTNNB1 CTNNA1 CDH1
33 10.21 ESR2 ESR1

GO Terms for Lobular Neoplasia

Cellular components related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.32 PGR MUC1 KRT5 HSP90AA1 ESR1 ERBB2
2 nucleus GO:0005634 10.3 PIP PGR MUC1 KRT5 HSP90AA1 ESR2
3 cell-cell junction GO:0005911 9.62 CTNND1 CTNNB1 CTNNA1 CASK
4 Schaffer collateral - CA1 synapse GO:0098685 9.58 CTNND1 CTNNB1 CASK
5 lamellipodium GO:0030027 9.56 CTNND1 CTNNB1 CTNNA1 CDH1
6 adherens junction GO:0005912 9.46 CTNND1 CTNNB1 CTNNA1 CDH1
7 presynaptic active zone cytoplasmic component GO:0098831 9.43 CTNND1 CTNNB1
8 zonula adherens GO:0005915 9.37 CTNND1 CTNNA1
9 flotillin complex GO:0016600 9.13 CTNNB1 CTNNA1 CDH1
10 catenin complex GO:0016342 8.92 CTNND1 CTNNB1 CTNNA1 CDH1

Biological processes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 ESR2 ESR1 CTNNB1 CDH1 BRCA2 BRCA1
2 regulation of apoptotic process GO:0042981 9.78 HSP90AA1 ESR1 CTNNB1 BRCA1
3 cell-cell adhesion GO:0098609 9.71 CTNND1 CTNNB1 CTNNA1 CDH1
4 response to estrogen GO:0043627 9.63 ESR1 CTNNA1 BRCA1
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.5 MUC1 BRCA2 BRCA1
6 adherens junction organization GO:0034332 9.46 CTNND1 CTNNB1 CTNNA1 CDH1
7 intracellular steroid hormone receptor signaling pathway GO:0030518 9.43 PGR ESR2 ESR1
8 chordate embryonic development GO:0043009 9.37 BRCA2 BRCA1
9 entry of bacterium into host cell GO:0035635 9.13 CTNND1 CTNNB1 CDH1
10 cellular response to indole-3-methanol GO:0071681 8.92 CTNNB1 CTNNA1 CDH1 BRCA1

Molecular functions related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.45 PRLR PIP PGR MUC1 KRT5 HSP90AA1
2 enzyme binding GO:0019899 9.83 PGR ESR2 ESR1 CTNNB1 BRCA1
3 nuclear receptor activity GO:0004879 9.58 PGR ESR2 ESR1
4 gamma-catenin binding GO:0045295 9.49 CTNNA1 CDH1
5 nitric-oxide synthase regulator activity GO:0030235 9.46 HSP90AA1 ESR1
6 steroid binding GO:0005496 9.43 PGR ESR2 ESR1
7 estrogen receptor activity GO:0030284 9.37 ESR2 ESR1
8 identical protein binding GO:0042802 9.36 PIP PGR HSP90AA1 ESR2 ESR1 ERBB2
9 steroid hormone receptor activity GO:0003707 9.33 PGR ESR2 ESR1
10 estrogen response element binding GO:0034056 9.32 ESR2 ESR1
11 beta-catenin binding GO:0008013 9.26 ESR1 CTNNB1 CTNNA1 CDH1

Sources for Lobular Neoplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....